cyrilzakka/clinical-trials huggingface dataset:
Body Composition Analysis and Time to Emergence From Remimazolam

Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.


Eligibility Criteria:
Inclusion Criteria:

* Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam

Exclusion Criteria:

* Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy
The Optimal Angle of Mediolateral Episiotomy at Crowning of the Head During Labor

In order to determine the optimal angle to perform an episiotomy, the investigators assessed the angle of marked episiotomy lines at the first stage of labor and at the time of crowning of the head.

Incision lines for mediolateral episiotomy were pre-marked on the perineal skin at 30°, 45°, and 60° angles from the midline, at the first stage of labor, in women with singleton pregnancies. The angles of the marked lines were measured again at crowning of the head. Mediolateral episiotomy was performed only for obstetric indications.


Eligibility Criteria:
Inclusion Criteria:

* women during labor above 37 weeks, Occiput presentation

Exclusion Criteria:

* cesarean section, vacuum or forceps deliver, breech deliver, below 37 weeks
Transperitoneal vs Retroperitoneal Laparoscopic or Robotic Partial Nephrectomy

Both laparoscopic partial nephrectomy (LPN) and robotic partial nephrectomy (RPN) can be performed through transperitoneal (TP) or retroperitoneal (RP) approach. RP approach is less utilized than TP approach because of technical difficulties when using rigid laparoscopic instruments in the small space of retroperitoneum cavity. However, with advanced surgical skills and thoughtful patient selection, RP approach may be associated with shorter operative time (OT), less estimated blood loss (EBL), shorter length of hospital stay (LOS) compared with TP approach.

Therefore, the investigators performed randomized control trial to compare the outcomes of the two approaches (TP-LPN or RPN vs RP-LPN or RPN).

Partial nephrectomy is the standard treatment for small renal masses. The evolution of minimally invasive partial nephrectomy led to widespread utilization of laparoscopic (LPN) and robotic partial nephrectomy (RPN). Both LPN and RPN can be performed through transperitoneal (TP) or retroperitoneal (RP) approach. RP approach is less utilized than TP approach because of technical difficulties when using rigid laparoscopic instruments in the small space of retroperitoneum cavity. However, with advanced surgical skills and thoughtful patient selection, RP approach may be associated with shorter OT, less EBL, shorter LOS compared with TP approach.

Therefore, the investigators performed randomized control trial to compare the outcomes of the two approaches (TP-LPN or RPN vs RP-LPN or RPN).

The purpose of this study To compare the treatment outcomes of the transperitoneal and retroperitoneal approach during LPN or RPN in treatment of small renal masses.

Inclusion criteria During the study period, a small renal mass (less than 4cm, T1a stage) patients are going to underwent LPN or RPN.

Exclusion criteria

1. Patients who underwent radical nephrectomy
2. Patients with bilateral renal masses
3. Patients with a solitary kidney
4. Patients reject a written informed consent
5. Pregnancy

The number of target subjects More than 106 patients who meet the inclusion criteria

Eligibility Criteria:
Inclusion Criteria:

* Patients are going to undergo LPN or RPN with renal mass =\<4cm

Exclusion Criteria:

* Bilateral renal masses Solitary kidney Previous underwent nephrectomy refuse to be enrolled the study pregnancy
Can Stories Encourage the Elderly to Vaccinate? Combining Viewer-tailored Personal Narrative Videos With Informational Videos to Improve Vaccine Uptake Among Older Adults

This study will compare the use of informational videos only, personal story videos only, and the combination of both, to see which is most effective in increasing vaccination among older adults.


Eligibility Criteria:
Inclusion Criteria:

* U.S. adults aged 50 and older

Exclusion Criteria:

* Participants who do not complete the survey
* Participants who are unable or refuse to view and listen to videos on the participant's device
Bright Light: A Novel Treatment for Anxiety

The primary aim of this research was to examine the influence of bright light on anxiety in high-anxious young adults. In an acute exposure study, participants were randomly assigned to 45 min of either (1) bright light (3,000 lux) or (2) a placebo inactivated negative ion generator. Treatments were initiated ≤1 hr after awakening. At 10 min before and 30 min after the treatments, state anxiety, mood, and blood pressure were assessed.

Following the acute exposure study, participants performed a 5-week study. Following a a 1-week baseline, participants were randomly assigned to four weeks of daily exposure to either (1) bright light (45 min/day; 3,000 lux) or (2) placebo inactivated negative ion generator, which were initiated ≤1 hr after awakening. Before and after the experiment, clinical ratings were conducted with the Hamilton Anxiety Scale, the Hamilton Depression Scale, and the Clinical Global Impressions scale (CGI). Following baseline, and following each week of treatment, blood pressure, as well as questionnaires for state anxiety, depression, mood, sleep, and side effects were assessed.


Eligibility Criteria:
Inclusion Criteria:

* Having a level of trait anxiety \[Spielberger State-Trait Anxiety Inventory (Form Y1)\]{23642} that was ≥ the 75th percentile for their age (i.e., ≥ 46 and ≥ 44 for women and men, respectively)

Exclusion Criteria:

* Current treatment for anxiety or depression;
* History of bipolar disorder, mania, or psychotic disorders;
* History of winter depression, which might bias towards positive response to light;
* Hypertension;
* Ophthalmic abnormalities; and
* Usual exposure to high levels of light such that the intervention would add little to usual exposure.
RELIABILITY AND VALIDITY OF THE DT BALANCE TEST IN PATIENTS WITH TKA

The ability to perform a cognitive task while walking simultaneously is essential in real daily life. However, the psychometric properties of dual-task walking tests have not been well established in patients undergoing total knee arthroplasty (TKA). The aim of study assess the test-retest reliability and validity of dual conditions TUG, 3MBWT, 8FWT nad 4SST in patients with TKA.


Eligibility Criteria:
Inclusion Criteria: TKA -

Exclusion Criteria: revision knee arthroplasty

-
Quality of Life for Pediatric Urolithiasis

The aim of this study is to assess the quality of life (QoL) in pediatric patients with urinary stone disease.

This study will assess the quality of life (QoL) in pediatric patients with urinary stone disease using the pediatric quality of life (PedsQol) questionnaire in comparison to normal healthy age/sex matched population.

Eligibility Criteria:
Inclusion Criteria:

* Patients who had urinary stones

Exclusion Criteria:

1. Patients presenting with obstructive uropathy or urosepsis.
2. Recent (less than 4 weeks) surgical intervention for urinary stone disease.
3. Indwelling urinary catheters or stents (urethral catheter, ureteral stents or nephrostomy tube).
4. Associated mental illness or cognitive dysfunction.
5. Associated chronic medical illness that may compromise QoL.
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

The purpose of this study is to correlate pathological features from specimens in order to determine if this new molecular diagnostic technique can be used to detect risk of skin cancer.

Squamous cell carcinoma is the culmination of a multistep carcinogenesis process that is preceded by early stages referred as squamous dysplasia and actinic keratosis. Squamous dysplasia (SD) also known as "field effect" is clinically characterized by xerosis (dry, scaly skin), lentigines and uneven pigmentation. While morphologically skin biopsies and cytology samples show only minimal changes, at the molecular level it is known that SD is characterized by small clone keratinocytes carrying mutations of the P53 gene. An optical technology called Partial Wave Spectroscopy (PWS) probes nanoscale structures in the order of tens to a few hundred nanometers. PWS is a light back-scattering techniques that uses light reflected off of a tissue sample. The measured biomarker is sensitive to the cytosolic and nucleic architecture within the cell and quantifies the nanoscale disorder, which conventional light microscopy fails to appreciate. PWS has allowed to identify various grades of structural disorder at the nanoscale level of colonic and pulmonary premalignant cell samples. Using PWS we aim to study the spectrum of cutaneous SD from patients at high risk for SCC development. Since squamous dysplasia is difficult to assess with routine histology and cytopathology and a grading system for squamous dysplasia by routine histology or cytology is not available, we propose to assess the value of PWS as a new and more sensitive imaging technique. By identifying the degree of SD at the molecular level, we may be able to intervene with close surveillance, early treatment and chemoprevention strategies to achieve lower morbidity by means of fewer and smaller skin cancers.

Eligibility Criteria:
Inclusion Criteria:

* 18 to 89 years old, male and female, Fitzpatrick skin phototype I - III
* Photodamage skin grades 3 - 4 (global assessment)
* Medical history of precancerous lesions and or known history of SCC or healthy volunteers

Exclusion Criteria:

* Subjects under 18 years old
* Pregnant women or lactating mothers
* Treatment with systemic chemotherapy within 4 weeks period before consent
* Known HIV+ patients (self-reported)
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)

This is a multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS. The study is planned to take place in multiple countries. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is aged 18 to 90 years.
2. Subject has an NIHSS of 6 to 25.
3. Subject is able to receive the first IP within 24 hours after stroke symptoms onset.

Neuroimaging Inclusion Criteria:

1. Subject is able to undergo a contrast brain perfusion with either MRI or computed tomography (CT).
2. Subject has Target Mismatch Profile on MRI (perfusion is included) or CTP: ischemic core volume ≤70 mL, mismatch ratio ≥1.2 and mismatch volume ≥5 mL.

Exclusion Criteria:

1. Subject has been treated or intent to treat with endovascular thrombectomy and/or intravenous thrombolytic during the current AIS.
2. Subject has a pre-stroke disability (mRS ≥2).
3. Subject has large ischemic core volume \>70 mL or ASPECTS ≤5.
4. Subject has symptoms of suspected subarachnoid hemorrhage.
5. Subject has imaging evidence of acute intracranial hemorrhage, intracranial tumor, arteriovenous malformations, other central nervous system lesions that could increase the risk of bleeding, or aneurysm requiring treatment.
6. Subject has significant mass effect with midline shift.
7. Subject has pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations.
8. Subject has current uncontrolled hypertension despite treatment.
9. Subject has INR \>1.7 or abnormal aPTT or platelet count \<100,000/mm\^3.
10. Subject has received conventional heparin or new oral anticoagulants within 48 hours before the first IP administration.
11. Subject has blood glucose concentration \<50 mg/dL or \>400 mg/dL.
12. Subject has moderate or severe hepatic, renal, and/or active infectious disease.
13. Subject is lactating, pregnant, or planning to become pregnant during the study.
14. Subject has had history of sICH, prior AIS, myocardial infarction, or serious head trauma within 90 days before Screening.
15. Subject has had any major surgery within 90 days before Screening.
16. Subject has had a bleeding event within 21 days before Screening.
17. Subject has puncture of noncompressible vessels within 7 days before Screening.
18. Subject has participated in another investigational study and received IP within 30 days before Screening or 5 half-lives (whichever is longer).
19. In the opinion of the Investigator, the subject is not appropriate for the study.
Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

The purpose of this study is to assess the relative bioavailability of the high concentration liquid formulation (HCLF) of gantenerumab produced with the G4 process in comparison to the same HCLF of gantenerumab produced with the G3 process in healthy participants following single SC dose administration.

This multi-center, randomized, open-label, single dose, parallel-group study will assess the relative bioavailability and the safety and tolerability of gantenerumab produced with the G4 process in comparison to gantenerumab produced with the G3 process. All participants will receive single SC dose of gantenerumab (manufactured by either the G3 or G4 process) on Day 1. The total duration of the study for each participant will be up to 21 weeks: Screening (up to 8 weeks); In-clinic period (Days -1 to 3); Out-patient period (Days 4 up to 68); and Safety Follow-up (up to 90 days after dosing).

Eligibility Criteria:
Inclusion Criteria:

* Healthy participant
* Body mass index (BMI) between 18.0 and 30.0 kilograms per meter-square (kg/m\^2), inclusive
* Body weight between 55 to 110 kg inclusive
* Female participants with either non-childbearing potential or with childbearing potential who commit to remain abstinent or use acceptable contraceptive methods during the treatment period and until at least 6 months after the follow-up visit
* Women of childbearing potential must have a negative serum pregnancy test result at screening and Day 1

Exclusion Criteria:

* History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, hematological or allergic disease, metabolic disorder, cancer, or cirrhosis
* History or suspicion of drugs of abuse addiction
* History or suspicion of alcohol addiction
* Pregnant or breastfeeding, or intending to become pregnant during the study or within 17 weeks after the last dose of study drug
* Prior administration of gantenerumab
* Clinically significant abnormalities (as judged by the investigator) in laboratory test results (including complete blood count, chemistry panel, and urinalysis)
* Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study
Examining the Effects of a Team-based Running Program

The investigators are interested in finding accessible interventions for youth and young adults that help promote long-term positive mental health functioning. They will be investigating the effects of Team Unbreakable, a 13-week, twice weekly running group, on mental health symptoms, memory, and attention. This intervention will hopefully improve mental health functioning in youth aged 17-25 that are at high risk of developing mental health disorders. Sessions will consist of 30 minutes of running under the supervision of group leaders and coaches. The group will steadily increase the distance and time spent running versus walking, with the goal of having everyone run a 5 km race together at the end of 13 weeks. Once a week, youth will be provided with education on a variety of topics related to health and running. Youth will complete measures before, during, and after the program to assess outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Healthy enough to participate in physical activity

Exclusion Criteria:

* NOT excluded on basis of mental health or addiction concerns
Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

We will rigorously test whether modulation of the motor cortex by transcranial direct current stimulation (tDCS) is an effective treatment for patients with chronic pelvic pain through the following specific aims:

A) The primary aim of this study is to determine whether transcranial direct current stimulation applied to the motor cortex in patients with chronic pelvic pain induces a significant decrease in the pain or symptoms as compared with sham tDCS. We will also measure changes in the clinical symptom scores of multiple pelvic organs, drug intake (narcotic), anxiety, depression, traumatic stress, as well as overall improvement in the quality of life to assess the effects of this treatment.

B) Determine the duration of the clinical effects of tDCS. We will therefore compare the amelioration of pain and related symptoms between active and sham tDCS for one year following treatment.

C) Determine whether tDCS changes the threshold for pain detection as compared with sham tDCS. Patients with chronic pelvic pain have a lower threshold for pain as compared to healthy subjects and we hypothesized that this threshold will increase after stimulation with tDCS.

D) Finally, we will examine whether 5 days of tDCS treatment is safe for use in chronic pelvic pain patients. Safety will be assessed through neuropsychological tests and adverse event reporting.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must be females between 18 and 55 years of age.
* Subjects must have a current VAS for pelvic pain of 5 or more.

Exclusion Criteria:

* Known pelvic malignancy.
* Patients with major depression with suicidal risk as clinically defined.
* Patients with other known, uncontrolled neuropsychiatric disorders.
* Abnormal neurological examination other than as signs of the condition studied in the present protocol.
* Contraindication to tDCS:
* A history of unmanaged substance abuse or dependence within the last 6 months.
* A history of previous treatment with tDCS.
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis

The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.

Study hypothesis was based on the following rationale:

* Psoriasis vulgaris is a chronic inflammatory skin disease with several extracutaneous manifestations and significant comorbidities (among others cardiovascular disease, metabolic syndrome, obesity and depression).
* An increased prevalence of smoking among psoriasis patients, as compared with healthy subjects, has been observed in several studies
* More recent studies suggest that cigarette smoking may trigger the development of psoriasis through oxidative, inflammatory and genetic mechanisms.Furthermore, smoking is associated with the clinical severity of psoriasis
* Smoking also contributes to higher morbidity and mortality from smoking related disorders in these patients There is now some evidence that patients with psoriasis who smoke tend to be less responsive to treatment

Eligibility Criteria:
Inclusion Criteria:

* Adult patients aged ≥18 years at the time of screening
* Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator
* Patients who are scheduled by their dermatologist to initiate treatment with Etanercept prescribed independently by the investigator as per local clinical practice guideline
* Stable plaque psoriasis for at least 2 months prior to Baseline
* Diagnosis of severe psoriasis defined as PASI \> 10
* Eligible for Etanercept treatment according to Summary of Product Characteristics (SmPC)
* Smokers with smoking \>10 cigarettes daily for smokers group (Group 1) or non-smokers for non-smoking group (Group 2)
* Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study

Exclusion Criteria:

* Previous or current treatment with antipsoriatic biologic drugs, such as Etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab.
* Exclusion Criteria according to the Enbrel® SmPC, with particular attention to: hypersensitivity to the active substance (etanercept) or to any of the excipients; sepsis or risk of sepsis, active infections, including chronic or localised infections.
* Positive pregnancy test, breast feeding or considering becoming pregnant during the study
* Clinically significant drug or alcohol abuse
Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus

The purpose of this study is to improve the therapeutic outcome of laser therapy for port wine stains by using a combination treatment of the pulsed dye laser (PDL), erbium yag laser and topical sirolimus.

In the first treatment period all patients will receive a total of five treatments with two week intervals. Every patient will receive the following four treatments (utilizing a template with separate squares of 1cm2): 1) PDL treatment followed by topical sirolimus application after Er:Yag laser ablation of the stratum corneum compared with 2) PDL treatment followed by topical sirolimus application without Er:Yag laser ablation of the stratum corneum, 3) PDL treatment only and 4) sirolimus application only. After the six months follow-up period, during the second treatment period, patients will receive an additional five treatments of the adjacent cosmetic unit of the treated part of the PWS, employing the most successful of the four treatment modalities as evaluated after the first treatment period.

Eligibility Criteria:
Inclusion Criteria:

* Subject has provided informed consent;
* Subject is ≥ 18 years of age at time of screening;
* Subject has an extra-facial homogenous Port Wine Stain (PWS);
* The PWS is large enough in size to fit one of the templates
* Subject has not received any laser treatment of the PWS in the last 3 months (in the treatment area);
* The PWS has a minimal erythema grading score of 3 (on a 4 point scale) in the opinion of the investigator;
* Screening blood safety values are within normal parameters or regarded as not clinically significant in the opinion of the investigator.

Exclusion Criteria:

* PWS with a nodular/hypertrophic component in the treatment area;
* PWS on cosmetically unacceptable locations in the opinion of the investigator;
* For women: pregnant or breast feeding during the treatment period;
* Women of child-bearing potential, unless they are using adequate contraceptive measures
* Subject is known to have immune deficiency, or is immune compromised
* Known allergy to sirolimus or other constituents of the study medication;
* Incapacitated subjects;
* Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.